Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-05-31T14:47:20.250Z Has data issue: false hasContentIssue false
  • English
  • Français

110 Implementation of Personalized Medicine in a Community Psychiatry Practice

Published online by Cambridge University Press:  24 April 2020

Audrey Umbreit ,
Shirshendu Sinha  and
Emily Holm
Audrey Umbreit
Affiliation:
Department of Pharmacy, Mayo Clinic Health System, Mankato, MN, USA
Shirshendu Sinha
Affiliation:
Department of Psychiatry and Psychology, Mayo Clinic Health System, Mankato, MN, USA
Emily Holm
Affiliation:
Department of Pharmacy, Mayo Clinic Health System, Mankato, MN, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To describe the initial results of implementing pharmacogenomics testing in a community-based psychiatry practice and potential impacts on medication management.

Method:

Retrospective chart review of prospectively maintained medical records of all adult patients with pharmacogenomics results from 9/01/2017 to 6/30/2019 under the care of psychiatrist and clinical pharmacist.

Results:

A total of 51 patients met inclusion criteria. A total of 7 pharmacokinetic genes and, due to changes in the test report over time, a range of 6-10 pharmacodynamic genes relevant to psychotropic medications were evaluated per patient. Every patient had genetic variations, with an average of 6.1 per patient (range 3-9; SD= 1.5). Patients were taking an average of 3.6 (range 1-8; SD=1.7) psychiatric medications at the time of the genetic test, to treat an average of 5 psychiatric conditions (range 1-9; SD=2.2). An average of 1.2 (range 0-4; SD=1.0) gene-drug interactions were uncovered per patient. Following review by psychiatrist and pharmacist, medication adjustments resulted in patients remaining on an average of 3.6 psychiatric medications, but decreasing the average number of gene-drug interactions per patient to 0.8 (range 0-3, SD=0.8).

Discussion:

The large number of genetic variations observed per patient is consistent with previous findings 1-2. The decrease in number of gene-drug interactions following testing demonstrates the practical utility of pharmacogenomics information to guide medication therapy. This study did not examine outcomes such as improvement in psychiatric condition or reduction in medication adverse effects; however, these endpoints have been evaluated in other trials 3-4.

Conclusions:

Pharmacogenomics testing presents an opportunity for a personalized medicine approach in a community-based psychiatry practice.

Type
Abstracts
Information
CNS Spectrums , Volume 25 , Issue 2 , April 2020 , pp. 271
Copyright
© Cambridge University Press 2020

References

References:

Bielinski, SJ., et.al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014;89(1):25-33.CrossRefGoogle ScholarPubMed
Van Driest, S.L., et.al. Clinical actionable genotypes among 10,000 patients with preemptive pharmacogenomics testing. Clinical Pharmacology & Therapeutics. 2014 Apr 95;95(4):423-431.CrossRefGoogle Scholar
Chiara, F., et.al. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology. 2018 Aug;28(8):945-954.Google Scholar
Altar, CA, et.al. Clinical utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from three clinical studies. Mol Neuropsychiatry. 2015 Oct;1(3):145 CrossRefGoogle ScholarPubMed